Anaplastic extramedullary plasmacytoma resistant to novel therapies: A case report
Oncologie
; 2023.
Article
in English
| EMBASE | ID: covidwho-2315641
ABSTRACT
The treatment of choice for extramedullary plasmacytoma (EMP) is radiotherapy (RT). It is under discussion whether the management of an anaplastic form of EMP requires the addition of systemic therapy. We present a case of a 66-year-old male who was diagnosed with anaplastic plasmacytoma of the maxillary sinus. After the exclusion of multiple myeloma, Dara-VMP (daratumumab, bortezomib, melphalan, and prednisolone) regimen was initiated. During the third cycle of Dara-VMP, a progression of the tumor was observed. RT and BRd (bendamustine, dexamethasone, and lenalidomide) regimen were initiated. After 4 cycles of BRd, disease progression was established. KRd (carfilzomib, lenalidomide, and dexamethasone) regimen was initiated. The first cycle of KRd was not completed, as the patient was diagnosed with COVID-19. After the infection, the progression of EMP was observed. In this case, the anaplastic EMP was resistant to RT and chemotherapy regimens with novel agents, including a monoclonal antibody, an immunomodulatory drug, and proteasome inhibitors. Copyright © 2023 the author(s), published by De Gruyter, Berlin/Boston.
anaplastic extramedullary plasmacytoma; case report; immunomodulatory drug; monoclonal antibody; novel therapies; proteasome inhibitor; radiotherapy; aged; article; cancer growth; cancer patient; cancer radiotherapy; chemotherapy; clinical article; coronavirus disease 2019; human; male; maxillary sinus; multiple myeloma; plasmacytoma; bendamustine; bortezomib; carfilzomib; daratumumab; dexamethasone; immunomodulating agent; lenalidomide; melphalan; prednisolone; unclassified drug
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Case report
Language:
English
Journal:
Oncologie
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS